The HCV Non-Nucleoside Inhibitor Tegobuvir Utilizes a Novel Mechanism of Action to Inhibit NS5B Polymerase Function

Tegobuvir (TGV) is a novel non-nucleoside inhibitor (NNI) of HCV RNA replication with demonstrated antiviral activity in patients with genotype 1 chronic HCV infection. The mechanism of action of TGV has not been clearly defined despite the identification of resistance mutations mapping to the NS5B...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Hebner, Christy M., Han, Bin, Brendza, Katherine M., Nash, Michelle, Sulfab, Maisoun, Tian, Yang, Hung, Magdeleine, Fung, Wanchi, Vivian, Randall W., Trenkle, James, Taylor, James, Bjornson, Kyla, Bondy, Steven, Liu, Xiaohong, Link, John, Neyts, Johan, Sakowicz, Roman, Zhong, Weidong, Tang, Hengli, Schmitz, Uli
Format: Artigo
Langue:Inglês
Publié: Public Library of Science 2012
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3374789/
https://ncbi.nlm.nih.gov/pubmed/22720059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0039163
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires